Assignee
RUBIUS THERAPEUTICS INC
US·16 granted patents·40 pending applications·195 citations·filing 2015–2023
Top patents by PatentIndex Score
56 records- 0198US9644180B2Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2015·Granted May 9, 2017·98 cites·21 claims
- 0297US10344263B2Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2017·Granted Jul 9, 2019·14 cites·25 claims
- 0397US10329531B2Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2017·Granted Jun 25, 2019·18 cites·29 claims
- 0497US10253296B2Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2017·Granted Apr 9, 2019·16 cites·24 claims
- 0596US10301594B1Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2018·Granted May 28, 2019·11 cites·29 claims
- 0695US10301593B2Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2018·Granted May 28, 2019·8 cites·27 claims
- 0794US10456421B2Compositions and methods related to engineered erythoid cells comprising 4-1BBLRUBIUS THERAPEUTICS INC·Filed 2017·Granted Oct 29, 2019·10 cites·20 claims
- 0893US10869898B2Methods and compositions for immunomodulationRUBIUS THERAPEUTICS INC·Filed 2015·Granted Dec 22, 2020·6 cites·25 claims
- 0992US10557119B2Erythroid cells comprising phenylalanine ammonia lyaseRUBIUS THERAPEUTICS INC·Filed 2019·Granted Feb 11, 2020·4 cites·27 claims
- 1092US10517897B1Methods related to engineered erythoid cells comprising 4-1BBLRUBIUS THERAPEUTICS INC·Filed 2019·Granted Dec 31, 2019·4 cites·28 claims
- 1190US10568910B2Compositions and methods related to engineered erythroid cells comprising IL-15RUBIUS THERAPEUTICS INC·Filed 2018·Granted Feb 25, 2020·3 cites·18 claims
- 1286US11141433B2Therapeutic cell systems and methods for treating cancer and infectious diseasesRUBIUS THERAPEUTICS INC·Filed 2019·Granted Oct 12, 2021·2 cites·30 claims
- 1383US2023293588A1Compositions and Methods Related to Multimodal Therapeutic Cell Systems for Cancer IndicationsRUBIUS THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1478US2022072048A1Compositions and Methods Related to Multimodal Therapeutic Cell Systems for Autoimmune IndicationsRUBIUS THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1575US10716811B2Compositions and methods related to multimodal therapeutic cancer indicationsRUBIUS THERAPEUTICS INC·Filed 2018·Granted Jul 21, 2020·0 cites·20 claims
- 1675US2020002674A1Erythroid cells comprising phenylalanine hydroxylaseRUBIUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1775US2019309262A1Erythroid cells comprising serine dehydrataseRUBIUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1875US2019309261A1Erythroid cells comprising lysine oxidaseRUBIUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1975US2019316091A1Erythroid cells comprising arginaseRUBIUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2075US2019376034A1Platelets comprising exogenous polypeptides and uses thereofRUBIUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2175US2019316090A1Erythroid cells comprising arginine deiminaseRUBIUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2274US2019388473A1Methods and compositions for immunomodulationRUBIUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2372US11020435B2Functionalized erythroid cellsRUBIUS THERAPEUTICS INC·Filed 2018·Granted Jun 1, 2021·1 cites·44 claims
- 2472US2018216067A1Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2572US2018265847A1Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2671US2020129556A1Compositions and methods related to engineered erythroid cells comprising il-15RUBIUS THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2771US2018187153A1Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2871US2018187154A1Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2970US2018187155A1Compositions and methods related to multimodal therapeutic cell systems for autoimmune indicationsRUBIUS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3068US2022073875A1Amplifiable RNAs for Therapeutic Cell SystemsRUBIUS THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3166US11576934B2Methods and compositions for immunomodulationRUBIUS THERAPEUTICS INC·Filed 2019·Granted Feb 14, 2023·0 cites·20 claims
- 3266US2016257932A1Genetically engineered enucleated erythroid cells comprising a phenylalanine ammonia lyase receiver polypeptideRUBIUS THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 3364US2022088076A1Therapeutic Cell Systems and Methods for Treating Cancer and Infectious DiseasesRUBIUS THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3464US2021180015A1Membrane-Receiver Complex TherapeuticsRUBIUS THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3563US11554141B2Methods and compositions for immunomodulationRUBIUS THERAPEUTICS INC·Filed 2018·Granted Jan 17, 2023·0 cites·18 claims
- 3663US2020345845A1Compositions and methods related to cell systems for penetrating solid tumorsRUBIUS THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3758US2019330591A1Amplifiable rnas for therapeutic cell systemsRUBIUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3858US2021290682A1Functionalized Erythroid CellsRUBIUS THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3958US2018153989A1Compositions and methods related to cell systems for penetrating solid tumorsRUBIUS THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4052US2020370016A1Methods of generating enucleated erythroid cellsRUBIUS THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4152US2020172597A1Artificial antigen presenting cells including hla-e and hla-g molecules and methods of useRUBIUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4251US2018135012A1Membrane-receiver complex therapeuticsRUBIUS THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 4350US2020338129A1Compositions including enucleated erythroid cellsRUBIUS THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4448US2019309271A1Therapeutic cell systems and methods for treating homocystinuriaRUBIUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4547US2021130780A1Methods of generating enucleated erythroid cells using myo-inositolRUBIUS THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4647US2021147802A1Methods of generating enucleated erythroid cells using taurine or hypotaurineRUBIUS THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4746US2019290686A1Artificial antigen presenting cells and methods of useRUBIUS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4846US2019062788A1Lipid nanoparticle methods and compositions for producing engineered erythroid cellsRUBIUS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4945US2019201548A1Gene editing and targeted transcriptional modulation for engineering erythroid cellsRUBIUS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 5044US2019161730A1Compositions and methods related to therapeutic cell systems expressing exogenous rnaRUBIUS THERAPEUTICS INC·Filed 2017·Application pending·0 cites
Showing the top 50 of 56 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when RUBIUS THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →